01 Nov2013
25 Oct2013
Regulations need clarity, says industry
A clinical trial can sometimes be the only option for a terminally ill patient, for whom death is just a matter of time, say advocates of clinical research.
“It is not unusual for executives of pharmaceutical companies to receive calls from cancer patients or their relatives inquiring about the possibility of participating in an ongoing trial,” says Dr Shoibal Mukherjee of Quintiles, a clinical research organisation.
Mukherjee says that patients who are part of the drug trial process often fare better than for those who are not because of the “focussed attention and meticulous follow-up that clinical trial participants get”.
